Ranibizumab has been proven to be effective in large multicentre studies. However, the
injections have to be repeated monthly. A combined therapy with the established photodynamic
therapy might even be more effective, less intravitreal injections might be necessary due to
a synergistic effect.
The study will be conducted to explore whether intravitreal ranibizumab in monotherapy or in
combination with verteporfin photodynamic therapy under a new time regime is an effective,
safe and convenient treatment for patients with subfoveal Choroidal Neovascularisation (CNV)
secondary to Age-Related Macular Degeneration (AMD).
Phase:
Phase 3
Details
Lead Sponsor:
The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery